Sort by
Keyphrases
Multiple Myeloma
74%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
68%
Diffuse Large B-cell Lymphoma (DLBCL)
57%
Overall Survival
56%
Multiple Myeloma Patients
48%
Chemotherapy
44%
Chimeric Antigen Receptor T Cells (CAR-T)
42%
Rituximab
38%
Progression-free Survival
37%
Relapsed or Refractory
32%
Relapsed or Refractory multiple Myeloma
31%
Bortezomib
31%
Lymphoma
28%
Hodgkin Lymphoma
25%
Hematological Malignancies
24%
Chimeric Antigen Receptor T-cell Therapy
24%
Clinical Outcomes
24%
During Pregnancy
23%
Non-Hodgkin Lymphoma
22%
Lymphoma Patients
22%
Lenalidomide
22%
Cyclophosphamide
22%
Follicular Lymphoma
21%
Myeloma
19%
Axicabtagene Ciloleucel
18%
Positron Emission Tomography-computed Tomography (PET-CT)
18%
Multicenter Retrospective Study
18%
Novel Agents
18%
Large B-cell Lymphoma
18%
Single Center
18%
Hazard Ratio
18%
Confidence Interval
18%
Median Overall Survival
17%
Mantle Cell Lymphoma
16%
Acute Myeloid Leukemia
16%
Israeli
16%
Pregnant Women
16%
Complete Response
16%
Newly Diagnosed multiple Myeloma
16%
Retrospective multicenter Study
16%
Adverse Events
16%
Prognostic Factors
15%
High Risk
15%
Stem Cell Transplantation
15%
Elderly Patients
15%
Protease Inhibitors
15%
Cytokine Release Syndrome
14%
Overall Response Rate
14%
Prednisone
14%
Multivariate Analysis
14%
Medicine and Dentistry
Multiple Myeloma
100%
Overall Survival
66%
Diseases
61%
Diffuse Large B-Cell Lymphoma
50%
Progression Free Survival
42%
Retrospective Study
33%
Hodgkin's Lymphoma
29%
Chimeric Antigen Receptor T-Cell
27%
Non-Hodgkin Lymphoma
25%
Hematologic Malignancy
24%
Myeloma
23%
Infection
23%
Autologous Stem Cell Transplantation
21%
Rituximab
21%
Hematopoietic Cell
20%
Acute Myeloid Leukemia
19%
Adverse Event
19%
Chimeric Antigen Receptor T-Cell Immunotherapy
19%
Large-Cell Lymphoma
19%
Follicular Lymphoma
19%
Cyclophosphamide
18%
Positron Emission Tomography-Computed Tomography
17%
Cell Transplantation
17%
Bortezomib
17%
Lenalidomide
17%
Clinical Trial
17%
Drug Megadose
16%
Prognostic Factor
16%
Allogeneic Stem Cell Transplantation
15%
Polyethylene Terephthalate
15%
Axicabtagene Ciloleucel
14%
Stem Cell Therapy
14%
Doxorubicin
14%
Prednisone
13%
Hazard Ratio
13%
Proteasome Inhibitor
13%
Myelodysplastic Syndrome
12%
B Cell Maturation Antigen
12%
Multivariate Analysis
12%
Malignant Neoplasm
12%
Cohort Analysis
11%
Chimeric Antigen Receptor
11%
Lymphoproliferative Disease
11%
Ovary Function
11%
Mantle Cell Lymphoma
11%
Allograft
11%
Light Chain
11%
Cytokine Release Syndrome
11%
Vincristine
10%
Dexamethasone
10%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
93%
Overall Survival
48%
Rituximab
41%
Diseases
40%
Chemotherapy
39%
Progression Free Survival
38%
Infection
37%
Chimeric Antigen Receptor
35%
Diffuse Large B Cell Lymphoma
31%
Bortezomib
26%
Adverse Event
24%
Lenalidomide
22%
Cyclophosphamide
21%
Clinical Trial
18%
Hodgkin Disease
18%
Retrospective Study
17%
Nonhodgkin Lymphoma
16%
Dexamethasone
16%
B Cell Maturation Antigen
15%
Amyloidosis
15%
Large Cell Lymphoma
14%
Chronic Lymphatic Leukemia
14%
Prednisone
14%
Acute Myeloid Leukemia
14%
Polyethylene Terephthalate
13%
Doxorubicin
13%
Hematologic Malignancy
13%
Axicabtagene Ciloleucel
12%
Messenger RNA
11%
Cytokine Release Syndrome
11%
Vincristine
11%
Mantle Cell Lymphoma
11%
Belantamab Mafodotin
11%
Myeloma
10%
Proteasome Inhibitor
10%
Neoplasm
10%
Lymphoproliferative Disease
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Remission
8%
Clinical Study
8%
Premature Ovarian Failure
8%
COVID-19 Vaccine
8%
Pomalidomide
8%
Myelodysplastic Syndrome
7%
Daratumumab
7%
Methotrexate
7%
Prospective Study
6%
Malignant Neoplasm
6%
Thrombocytopenia
6%
Fluorine 18
6%